EP2723349A4 - Microrna-31 compositions and methods for use in autoimmune disease - Google Patents

Microrna-31 compositions and methods for use in autoimmune disease

Info

Publication number
EP2723349A4
EP2723349A4 EP12804592.9A EP12804592A EP2723349A4 EP 2723349 A4 EP2723349 A4 EP 2723349A4 EP 12804592 A EP12804592 A EP 12804592A EP 2723349 A4 EP2723349 A4 EP 2723349A4
Authority
EP
European Patent Office
Prior art keywords
microrna
compositions
methods
autoimmune disease
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12804592.9A
Other languages
German (de)
French (fr)
Other versions
EP2723349A2 (en
Inventor
Yihong Yao
Nan Shen
Wei Fan
Yuanjia Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2723349A2 publication Critical patent/EP2723349A2/en
Publication of EP2723349A4 publication Critical patent/EP2723349A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
EP12804592.9A 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease Withdrawn EP2723349A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
PCT/US2012/044197 WO2013003346A2 (en) 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease

Publications (2)

Publication Number Publication Date
EP2723349A2 EP2723349A2 (en) 2014-04-30
EP2723349A4 true EP2723349A4 (en) 2015-01-14

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12804592.9A Withdrawn EP2723349A4 (en) 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease

Country Status (8)

Country Link
EP (1) EP2723349A4 (en)
JP (1) JP2014521600A (en)
KR (1) KR20140066671A (en)
AU (1) AU2012275552A1 (en)
BR (1) BR112013033794A2 (en)
CA (1) CA2841158A1 (en)
RU (1) RU2014102217A (en)
WO (1) WO2013003346A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104208A1 (en) * 2019-11-26 2021-06-03 中国科学院上海营养与健康研究所 Endogenous small rna molecular target for preventing skin aging and premature aging and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030153A1 (en) * 2007-08-27 2009-03-12 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences The roles of mirnas in the diagnosis and treatment of systemic lupus erythematosus
WO2010065961A2 (en) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030153A1 (en) * 2007-08-27 2009-03-12 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences The roles of mirnas in the diagnosis and treatment of systemic lupus erythematosus
WO2010065961A2 (en) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FAN WEI ET AL: "Identification of microRNA-31 as a Novel Regulator Contributing to Impaired IL-2 Production in T cells From Patients With Systemic Lupus Erythematosus", ARTHRITIS & RHEUMATISM, vol. 63, no. 10, Suppl. S, 1922, October 2011 (2011-10-01), & 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, pages S749 - S750, XP002731678 *
GOMEZ-MARTIN D ET AL: "Interleukin 2 and systemic lupus erythematosus", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 1, 1 September 2009 (2009-09-01), pages 34 - 39, XP026574987, ISSN: 1568-9972, [retrieved on 20090306], DOI: 10.1016/J.AUTREV.2009.02.035 *
RUJUAN DAI ET AL: "Identification of a Common Lupus Disease-Associated microRNA Expression Pattern in Three Different Murine Models of Lupus", PLOS ONE, vol. 5, no. 12, 10 December 2010 (2010-12-10), pages e14302, XP055148831, DOI: 10.1371/journal.pone.0014302 *
S. VALASTYAN ET AL: "Concurrent Suppression of Integrin 5, Radixin, and RhoA Phenocopies the Effects of miR-31 on Metastasis", CANCER RESEARCH, vol. 70, no. 12, 15 June 2010 (2010-06-15), pages 5147 - 5154, XP055148658, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0410 *
WEI FAN ET AL: "Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, vol. 64, no. 11, 27 October 2012 (2012-10-27), pages 3715 - 3725, XP055148804, ISSN: 0004-3591, DOI: 10.1002/art.34596 *

Also Published As

Publication number Publication date
KR20140066671A (en) 2014-06-02
JP2014521600A (en) 2014-08-28
CA2841158A1 (en) 2013-01-03
WO2013003346A2 (en) 2013-01-03
WO2013003346A3 (en) 2013-02-28
RU2014102217A (en) 2015-08-10
BR112013033794A2 (en) 2019-09-24
AU2012275552A1 (en) 2014-02-06
EP2723349A2 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
HK1201152A1 (en) Dermal delivery compositions and methods
HK1199694A1 (en) Probiotic compositions and methods
IL230237B (en) Brown fat cell compositions and methods
EP2536293A4 (en) Methods and compositions for use in aquaculture
EP2665726A4 (en) Compositions and methods for cardiovascular disease
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
HK1220912A1 (en) Methods and compositions for reducing body fat
HK1204892A1 (en) Improvements in and relating to cushions
HK1199378A1 (en) Compositions and methods for use in promoting lean body mass
ZA201307187B (en) Synergistic compositions and methods
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2629742A4 (en) Hair-mending compositions and associated methods
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2739318A4 (en) In line sterlizer
HUE041627T2 (en) Cleaning compositions and methods
GB201117106D0 (en) Prosthesis and methods and uses involving said prosthesis
EP2678339A4 (en) Methods and compositions for treating -thalassemia and sickle cell disease
EP2668044A4 (en) Compositions and their use
ZA201308892B (en) Compositions and methods
ZA201305342B (en) Improvements in and relating to compositions
EP2766357A4 (en) Meso-biliverdin compositions and methods
IL227384A0 (en) Metal-passivating cmp compositions and methods
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
EP2723349A4 (en) Microrna-31 compositions and methods for use in autoimmune disease
PL2688418T3 (en) Stigmasterol-rich phytosterol composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7088 20060101AFI20141128BHEP

Ipc: C12N 15/113 20100101ALI20141128BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20141212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150723